Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

312.47 +0.31 (+0.10%)
Streaming Delayed Price Updated: 11:05 AM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 128,715
Open 313.00
Bid (Size) 312.47 (2)
Ask (Size) 312.70 (2)
Prev. Close 312.16
Today's Range 312.47 - 315.15
52wk Range 233.01 - 325.19
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Top Growth Stock Is Targeting a Multi-Billion-Dollar Market. Here's What It Means for Investors
It wouldn't be the first time the company finds success in a lucrative area. 
Via The Motley Fool
Have $2,000? 2 Exceptional Stocks to Buy In a Bear Market
The current market is challenging investors' fortitude, but patience can pay off. 
Via The Motley Fool

Performance

YTD
+9.25%
+9.25%
1 Month
+7.64%
+7.64%
3 Month
+8.09%
+8.09%
6 Month
+6.72%
+6.72%
1 Year
+21.81%
+21.81%

More News

Read More
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
Via Investor's Business Daily
What Bear Market? These 2 Winning Stocks Are Still Worth Buying.
Via The Motley Fool
2 Top Stocks to Buy With $1,000 Right Now
Via The Motley Fool
2 No-Brainer Stocks to Buy Before the Next Bull Market
Via The Motley Fool
Why Bluebird Bio Shares Are Plunging Today
Via Benzinga
Here's How Much $100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
How Is The Market Feeling About Vertex Pharmaceuticals?
Via Benzinga
10 Analysts Have This to Say About Vertex Pharmaceuticals
Via Benzinga
2 No-Brainer Growth Stocks to Buy and Hold for Years
Via The Motley Fool
The 3 Best Growth Stocks to Buy in the Biotech Sector
Via InvestorPlace
Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie
Via The Motley Fool
Alkermes Stock Sees Rising Relative Strength Rating
Via Investor's Business Daily
3 Small Financial Software Makers Showing Strong Chart Action
Via MarketBeat
Bullish News May Push Vertex Pharmaceuticals Above 52-Week High
Via MarketBeat
Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
Via Investor's Business Daily
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Could CRISPR Therapeutics Become the Next Moderna?
Via The Motley Fool
Want $1 Million in Retirement? Buy and Hold These 5 Stocks
Via The Motley Fool
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Via InvestorPlace
Nasdaq Bear Market: 2 Growth Stocks to Buy That Keep Bucking the Trend
Via The Motley Fool
This Is My Highest-Conviction Stock to Own in 2023 and Beyond
Via The Motley Fool
Got $3,000? 3 Growth Stocks to Double Up on Right Now
Via The Motley Fool
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.